IQuum Gets FDA Emergency Use OK for H1N1 Molecular Assay | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – IQuum, a privately held molecular diagnostics firm, has gained Emergency Use Authorization from the US Food and Drug Administration for its Liat Influenza A/2009 H1N1 Assay.

The nucleic acid test can be performed from sample to result in 26 minutes. According to the firm, the Liat assay can detect and differentiate 2009 H1N1 influenza viral RNA from nasopharyngeal swab samples and has shown 100 percent agreement with an EUA comparator assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of 200 bird species, and more.

The Australian High Court rules that isolated genetic material cannot be patented.

The startup incubator Y Combinator is launching a nonprofit research lab.

In Genome Research this week: vervet genome, tandem repeats affect gene expression in great apes, and more.

Sponsored by

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit. 

Sponsored by

This webinar will focus on a range of research and clinical applications enabled by improvements in mate pair technology for whole genome sequencing. 

Sponsored by
Oracle Health Sciences

Brian Wells of Penn Medicine will detail how his team's "PennOmics" integrated healthcare data warehouse accelerates clinical trial recruitment at the point of care, accepts data from wearables, and does it all in a secure, HIPAA- and research-compliant fashion.